|

Anti-KRAS G12V mTCR PBL Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Gastrointestinal Cancer1
  • Rectal Cancer1
  • Pancreatic Cancer1
  • Colon Cancer1
  • Gastric Cancer1

Bethesda, Maryland1 trial

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.